Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 43 - Drugs for specific purposes, not provided for in groups
Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317)
09/2000
09/26/2000US6124329 Metalloproteinase inhibitors
09/26/2000US6124320 Treating with non-sedating antihistamines without causing cardiac arrhythmias
09/26/2000US6124316 Compounds which are specific antagonists of the human NK3 receptor and their use as medicinal products and diagnostic tools
09/26/2000US6124314 Osteoporosis compounds
09/26/2000US6124312 Heterocyclic compounds
09/26/2000US6124307 Nonnucleoside inhibitors of reverse transcriptase, composite binding pocket and methods for use thereof
09/26/2000US6124299 Calcitonin mimetics
09/26/2000US6124296 Arylglycinamide derivatives, methods of producing these substances and pharmaceutical compositions containing such compounds
09/26/2000US6124288 Phosphodiesterase iv inhibitors
09/26/2000US6124285 Indole-2,3-dione-3-oxime derivatives
09/26/2000US6124283 Substituted 1,2,3,4-tetrahydronaphthalene derivatives
09/26/2000US6124281 Azolobenzazepine derivatives as neurologically active agents
09/26/2000US6124279 Neurokinin a antagonists, antiasthmatic agents
09/26/2000US6124278 Acylbenzoxazines for enhancing synaptic response
09/26/2000US6124270 Use of a cationic amphipathic compound as a transfection agent, vaccine additive or drug
09/26/2000US6124266 Sulphoquinovosyldiacylglycerol (sqdg) useful for prophylaxis or treatment of atopic dermatitis, urticaria and psoriasis, and as an antiproliferative agent
09/26/2000US6124264 Growth hormone secretagogue in a human or other animal to treat osteoporosis, congestive heart failure, aging, obesity; bone and wound healing agents
09/26/2000US6124263 Treatment of tumors by administration of growth hormone releasing compounds and their antagonists
09/26/2000US6124256 Administering an agonist specific for somatostatin (sst) receptor(s) showing an increased expression in the vascular wall subsequent to injury or surgery
09/26/2000US6124101 Diagnosis of thrombosis in a mammals; incubating a sample of fluid with an antibody that preferentially binds a cleaved activation peptide, counting antibody bound cleaved activation peptides, compare to control
09/26/2000US6123959 Phospholipids, and competitive inhibitor(s) including arbutin of an enzyme for the synthesis of melanin, tyrosinase and non-competitive inhibitor(s) of tyrosinase selected from specified substituted 4-oxo-chromene compounds
09/26/2000US6123943 NF-KB activity inhibitor
09/21/2000WO2000055634A1 Grb14 and the insulin receptor and screening of novel medicines
09/21/2000WO2000055633A2 Methods of screening for colorectal cancer modulators
09/21/2000WO2000055371A1 27 human secreted proteins
09/21/2000WO2000055330A1 Polysaturated fatty acid (pufa) elongase from caenorhabditis elegans
09/21/2000WO2000055321A2 Vertebrate protein slit, dna sequence encoding it and uses thereof
09/21/2000WO2000055201A1 49 human secreted proteins
09/21/2000WO2000055198A1 50 human secreted proteins
09/21/2000WO2000055195A1 Compositions for promoting nerve regeneration
09/21/2000WO2000055194A2 Tuberculosis antigens and methods of use therefor
09/21/2000WO2000055171A1 50 human secreted proteins
09/21/2000WO2000055161A1 6-substituted biaryl purine derivatives as potent cyclin/cdk inhibitors and antiproliferative agents
09/21/2000WO2000055159A2 Substituted aza-oxindole derivatives
09/21/2000WO2000055155A2 Heterocyclic compounds as adenosine deaminase inhibitors
09/21/2000WO2000055153A1 Amide derivatives
09/21/2000WO2000055152A1 Aromatic heterocyclic compounds as anti-inflammatory agents
09/21/2000WO2000055149A1 Dimeric compounds and as inhibitors of neuraminidase
09/21/2000WO2000055147A1 Fused 1,4-thiazine-2-carbonitrile derivatives, their preparation and use
09/21/2000WO2000055144A1 Amine derivatives as protease inhibitors
09/21/2000WO2000055139A2 Heterocyclic urea and related compounds useful as anti-inflammatory agents
09/21/2000WO2000055137A1 Compounds and methods for modulation of estrogen receptors
09/21/2000WO2000055134A1 Substituted 1-oxo- and 1,3-dioxoisoindolines and their use in pharmaceutical compositions for reducing inflammatory cytokine levels
09/21/2000WO2000055129A1 Dithiocarbonimidate derivatives
09/21/2000WO2000055126A2 N-cyanomethylamides as protease inhibitors
09/21/2000WO2000055125A2 N-cyanomethyl amides as protease inhibitors
09/21/2000WO2000055120A1 Amide derivatives
09/21/2000WO2000055118A1 Nuclear receptor arylating compounds
09/21/2000WO2000055114A1 Substituted 2-aminobenzamide caspase inhibitors and the use thereof
09/21/2000WO2000055072A2 Aerosol metering valve
09/21/2000WO2000054809A1 Cervical ripening agent and cervical ripening method
09/21/2000WO2000054808A1 Prostaglandin ep4 receptor agonist and treatment method
09/21/2000WO2000054806A1 Insulin-like growth factor binding protein-4 protease
09/21/2000WO2000054796A1 Novel antiangiogenic peptides
09/21/2000WO2000054794A1 Wafer delivery system
09/21/2000WO2000054782A1 Treatment of accidental extravasation of anthracyclines
09/21/2000WO2000054774A1 Apomorphine and sildenafil composition
09/21/2000WO2000054769A1 Protease inhibitors
09/21/2000WO2000054767A1 Use of lipoxin compounds for inhibiting of tnf-(alfa) initiated neutrophil response
09/21/2000WO2000054761A2 Regulation of phospholipase d activity
09/21/2000WO2000054756A2 Nitrate esters and their use for introducing neuroprotection and cognition enhancement
09/21/2000WO2000040716A3 Soluble receptor br43x2 and methods of using them for therapy
09/21/2000WO2000040225A3 Inhibition of tnf activity
09/21/2000WO2000039292A3 Antisense oligonucleotide for inhibiting the expression of the adhesion molecule very late antigen 4 (vla-4) in human cells
09/21/2000WO2000039154A3 Peptides of the at1 receptor and their use for preeclampsia and malign hypertension
09/21/2000WO2000038785A3 Methods for treating certain diseases using naaladase inhibitors
09/21/2000WO2000027868A3 Connective tissue growth factor (ctgf) and methods of use
09/21/2000WO2000020598A9 Peptides useful for reducing symptoms of toxic shock syndrome and septic shock
09/21/2000WO2000015792A3 Promotion or inhibition of angiogenesis and cardiovascularization
09/21/2000WO2000010551A3 Methods of using and compositions comprising dopamine reuptake inhibitors
09/21/2000WO2000001668A3 Naaladase inhibitors useful as pharmaceutical compounds and compositions
09/21/2000WO1999039706A9 Pharmaceuticals comprising n,n'-bis(2- hydroxybenzyl) ethylenediamine-n, n'-diacetic acid for iron chelating therapy
09/21/2000CA2747376A1 Use of lipoxin compounds for inhibiting of tnf-(alpha) initiated neutrophil response
09/21/2000CA2369319A1 Novel methods of diagnosing colorectal cancer, compositions, and methods of screening for colorectal cancer modulators
09/21/2000CA2368148A1 Novel compounds and compositions as protease inhibitors
09/21/2000CA2368122A1 Novel compounds and compositions as protease inhibitors
09/21/2000CA2368068A1 27 human secreted proteins
09/21/2000CA2367895A1 Compounds and methods for modulation of estrogen receptors
09/21/2000CA2367605A1 Apomorphine and sildenafil composition
09/21/2000CA2367409A1 Metering valve
09/21/2000CA2367354A1 6-substituted biaryl purine derivatives as potent cyclin/cdk inhibitors and antiproliferative agents
09/21/2000CA2367352A1 Amine derivatives as protease inhibitors
09/21/2000CA2367340A1 Substituted 2-aminobenzamide caspase inhibitors and the use thereof
09/21/2000CA2367213A1 Novel antiangiogenic peptides
09/21/2000CA2365214A1 Vertebrate protein slit, dna sequence encoding it and uses thereof
09/21/2000CA2365096A1 Polyunsaturated fatty acid (pufa) elongase from caenorhabditis elegans
09/21/2000CA2364630A1 50 human secreted proteins
09/21/2000CA2364549A1 50 human secreted proteins
09/21/2000CA2363022A1 49 human secreted proteins
09/21/2000CA2361819A1 Amide derivatives
09/21/2000CA2361289A1 Compositions for promoting nerve regeneration
09/21/2000CA2332427A1 Prostaglandin ep4 receptor agonist and treatment method
09/21/2000CA2332375A1 Cervical ripening agent and cervical ripening method
09/20/2000EP1036783A1 Crystalline hydrated dihydroxy open-acid simvastatin calcium salt
09/20/2000EP1036564A1 Thyromimetic antiobesity agents
09/20/2000EP1036558A1 Anhydrous composition for decoloration of ceratinic fibers comprising a combination of a hydrosoluble thickening polymer and an amphiphilic nonionic polymer carrying a fatty grain
09/20/2000EP1036557A1 Preemulsion and its use for making hair dyes as well as a method for making hair dye emulsions
09/20/2000EP1036191A2 Method for identifying ihbitors of g-protein coupled receptor hibef51
09/20/2000EP1036178A1 Identification of lysolipid receptors involved in inflammatory response
09/20/2000EP1036177A1 Novel vectors and genes exhibiting increased expression
1 ... 1128 1129 1130 1131 1132 1133 1134 1135 1136 1137 1138 1139 1140 1141 1142 1143 1144 1145 1146 1147 1148 ... 1564